Chemosensitization prevents tolerance of Aspergillus fumigatus to antimycotic drugs

Jong Kim, Bruce Campbell, Noreen Mahoney, Kathleen Chan, Russell Molyneux, Gregory May

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

Tolerance of human pathogenic fungi to antifungal drugs is an emerging medical problem. We show how strains of the causative agent of human aspergillosis, Aspergillus fumigatus, tolerant to cell wall-interfering antimycotic drugs become susceptible through chemosensitization by natural compounds. Tolerance of the A. fumigatus mitogen-activated protein kinase (MAPK) mutant, sakAΔ, to these drugs indicates the osmotic/oxidative stress MAPK pathway is involved in maintaining cell wall integrity. Using deletion mutants of the yeast, Saccharomyces cerevisiae, we first identified thymol and 2,3-dihydroxybenzaldehyde (2,3-D) as potent chemosensitizing agents that target the cell wall. We then used these chemosensitizing agents to act as synergists to commercial antifungal drugs against tolerant strains of A. fumigatus. Thymol was an especially potent chemosensitizing agent for amphotericin B, fluconazole or ketoconazole. The potential use of natural, safe chemosensitizing agents in antifungal chemotherapy of human mycoses as an alternative to combination therapy is discussed.

Original languageEnglish (US)
Pages (from-to)266-271
Number of pages6
JournalBiochemical and biophysical research communications
Volume372
Issue number1
DOIs
StatePublished - Jul 18 2008

Keywords

  • Antifungal chemotherapy
  • Aspergillus fumigatus
  • Chemosensitization
  • Combination therapy
  • MAPK
  • Natural compounds

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Chemosensitization prevents tolerance of Aspergillus fumigatus to antimycotic drugs'. Together they form a unique fingerprint.

Cite this